Robert F. Leibenluft
Bob Leibenluft's antitrust practice is unusual in that it focuses on only one industry — healthcare and life sciences — yet it spans all industry sectors, including providers, payers, and drug and device manufacturers. He brings over 35 years of experience, including heading the FTC Healthcare Division, to his representation of clients in counseling, investigations, transactions, and litigation matters.
Starting at the firm in 1981 as a health regulatory lawyer, Bob became a nationally recognized lawyer on Medicare issues. His deep understanding of the industry was a reason he was asked to lead the FTC Healthcare Division in the mid-1990s, where he supervised drafting of the FTC/DOJ Health Policy Statements, which first addressed clinical integration, and led investigations of hospital mergers and physician networks.
On a pro bono basis, Bob has led a 10-year review of the D.C. government's response to HIV/AIDs, advised the Government of Liberia on a new public health law, and provided antitrust advice to the CEO Roundtable on Cancer.
Chambers USA describes Bob as "renowned for his expertise in healthcare antitrust and is singled out by a source as someone who really knows how the system works" and who is hailed by peers as a "terrific healthcare antitrust lawyer."
Bob is an inaugural fellow and former vice president of the American Health Lawyers Association. He is a former Chair of the ABA Antitrust Section's Health and Pharmaceuticals Committee, Joint Conduct Committee, and State Enforcement Committee. Bob is currently Chair of the Board of Directors of HCI3, the parent of Prometheus Payment, and Bridges-to-Excellence. He teaches the course Antitrust in the Healthcare Sector at George Washington School of Law, where he is an adjunct professor.
"Robert Leibenluft 'is the tops,' according to interviewees, who particularly praise his deep expertise in antitrust law. He regularly handles related litigation and general counseling for clients across all areas of healthcare."
"One of the best lawyers for antitrust matters."
Counseling numerous pharmaceutical companies regarding patent litigation settlements.
Counseling numerous drug and device manufacturers on pricing policies, including loyalty and volume discounts, bundling, and price discrimination.
Advising hospitals, physicians, health plans, and life science companies on merger clearance, HSR filings, and due diligence and integration planning.
Advising numerous physician networks and physician/hospital organizations regarding clinical integration.
Represented Advocate Health Partners in FTC investigation and litigation with a private health plan regarding its clinical integration program.
Technical advisor to grantees on RWJF Aligning Forces for Quality program re antitrust issues raised by employer/provider/health plan collaborations.
Defended several health plans in investigations by DOJ and state attorney generals regarding most-favored nation provisions.
Defended American Society for Reproductive Medicine in class action challenging ethical guideline on payments for egg donors; defeated damages class.
Healthcare: Regulatory & Litigation
Washington's Top Lawyers: Health Care
Washington, D.C. Super Lawyers
Washington, D.C. Super Lawyers
The Best Lawyers in America
Healthcare and Life Sciences
Legal 500 US
Top 25 for Health Care
Best of the Best USA
Outstanding Health Care Antitrust Lawyer
Nightingale's Health Care News